Showing posts with label Vaccine. Show all posts
Showing posts with label Vaccine. Show all posts

Tuesday, June 25, 2013

Egg-Free Flu Vaccine Ready for Flu Season

By Todd Neale, Senior Staff Writer, MedPage Today

A new trivalent recombinant influenza vaccine has been added to the 2013-2014 flu recommendations to provide an immunization option for people with a history of allergic reactions to eggs.

Flublok is made using recombinant DNA technology and contains hemagglutinin produced in an insect cell line. Approved by the FDA in January, it is the only completely egg-free flu vaccine available, prompting the Advisory Committee on Immunization Practices (ACIP) to add it to the guidance for the upcoming season at one of its regular meetings at CDC headquarters in Atlanta.

According to the previous algorithm for determining how people with egg allergies should be vaccinated, those who had a history of only hives upon exposure to egg were recommended to get inactivated influenza vaccine followed by an observation period of at least 30 minutes after administration to watch for reactions.

And those who had a history of some other reaction aside from hives -- such as cardiovascular changes, respiratory distress, gastrointestinal symptoms, and reactions requiring epinephrine or emergency medical attention -- were recommended to see a physician with expertise in management of allergic conditions for further evaluation.

For the upcoming season -- following a unanimous vote by ACIP -- Flublok (abbreviated RIV3) will be listed as an alternative in both scenarios, assuming the individual falls within the approved age range of 18 to 49.

A reference to RIV3 also will be made in added language referring to people who do not have a history of egg allergy but who may be at risk based on previously performed allergy testing. In that case, "consultation with a physician with expertise in the management of allergic conditions should be obtained prior to vaccination" or, if age appropriate, RIV3 can be given.

At the last meeting of ACIP in February, the committee approved the addition of four recently approved flu vaccines to the guidance for the 2013-2014 season. On Thursday, Sanofi Pasteur's Fluzone Quadrivalent -- approved by the FDA earlier this month -- was added, as well. It is the only quadrivalent flu vaccine approved for use in children younger than 2.

All of the quadrivalent vaccines will protect against two A strains -- H1N1 and H3N2 -- and two B strains -- one from the Yamagata lineage and one from the Victoria lineage.

One of the ACIP members, Tamera Coyne-Beasley, MD, MPH, reported that her institution, the University of North Carolina at Chapel Hill, receives clinical trial funding from Merck. The other committee members reported that they had no conflicts of interest.

Todd Neale

Senior Staff Writer

Todd Neale, MedPage Today Staff Writer, got his start in journalism at Audubon Magazine and made a stop in directory publishing before landing at MedPage Today. He received a B.S. in biology from the University of Massachusetts Amherst and an M.A. in journalism from the Science, Health, and Environmental Reporting program at New York University.

Friday, June 21, 2013

Big Drop in HPV, Vaccine Gets Credit (CME/CE)

Register Today

Earn Free CME Credits by reading the latest medical news
in your specialty.

Sign Up
By Charles Bankhead, Staff Writer, MedPage Today Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San FranciscoThe HPV infection in young women has declined by more than half since the introduction of the HPV vaccine, despite low vaccine uptake.Point out that the decline in HPV infection rate occurred despite the fact that only a third of eligible patients received the vaccine.

ATLANTA -- The prevalence of human papillomavirus (HPV) infection in young women has declined by more than half since the introduction of the HPV vaccine, despite low vaccine uptake, according to a study by the CDC.

Compared with the 4 years prior to the vaccine's introduction, infection with the HPV strains covered by the vaccine decreased by 56% in 14- to 19-year-old girls in the first 4 years after the vaccine became available.

The decline in HPV infection rate occurred despite the fact that only a third of eligible patients received the vaccine.

HPV prevalence in other age groups did not differ significantly between the two time periods, the CDC announced at a press briefing and reported simultaneously in the Journal of Infectious Disease.

"This report shows that HPV vaccine works well, and the report should be a wake-up call to our nation to protect the next generation by increasing HPV vaccination rates," CDC director Tom Frieden, MD, said in a statement. "Unfortunately only one-third of girls ages 13 to 17 have been fully vaccinated with HPV vaccine. Countries such as Rwanda have vaccinated more than 80% of their teen girls.

"Our low vaccination rates represent 50,000 preventable tragedies -- 50,000 girls alive today will develop cervical cancer over their lifetime that would have been prevented if we reach 80% vaccination rates. For every year we delay in doing so, another 4,400 girls will develop cervical cancer in their lifetimes."

Introduced in 2006, the first FDA-approved HPV vaccine covered the four viral strains most closely associated with gynecologic cancer (HPV-6, 11, 16, and 18). In June of that year the Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination of 11- and 12-year-old girls with three doses of the quadrivalent vaccine, and catch-up vaccination of girls and young women 13 through 26.

In 2009 the ACIP updated the recommendation to include the bivalent vaccine (HPV-16 and 18). Two years later, ACIP recommended routine vaccination of boys and young men.

A national survey in 2010 showed that 49% of females 13 to 17 had received at least one dose of an HPV vaccine (primarily the quadrivalent vaccine), and 32% had received all three doses.

Previous studies of type-specific prevalence of HPV infection occurred in the pre-vaccine era. The National Health and Nutrition Survey Evaluation (NHANES) provided an opportunity to estimate the impact of HPV vaccination on the prevalence of infection.

Lauri E. Markowitz, MD, of the CDC, and colleagues compared data on HPV prevalence from the pre-vaccine era (NHANES 2003 to 2006) with prevalence derived from 2007 to 2010 NHANES data. During both survey periods, HPV infection was assessed by linear array HPV assay of cervicovaginal swabs from females 14 to 59. The investigators found that 4,150 participants provided usable swabs during 2003 to 2006 and 4,253 during 2007 to 2010.

To assess vaccine uptake, the investigators interviewed NHANES participants age 16 and older and younger participants who were independent, as well as the parents or guardians of minors.

Overall, the prevalence of HPV infection was 42.5% during 2003 to 2006 and 39.8% during 2007 to 2010, a nonsignificant difference.

Stratification by age group showed a consistent reduction in HPV infection among females 14 to 19: Any HPV infection -- 32.9% in the pre-vaccine period to 26.1% during 2007 to 2010 (HR 0.79, 95% CI 0.66-0.95, P=0.01)HPV strains in the vaccine -- 11.5% to 5.1% (HR 0.44, 95% CI 0.31-0.62, P<0.001)High-risk HPV strains included in the vaccine -- 7.2% to 3.6% (HR 0.50, 95%f CI 0.34-0.74, P<0.001)High-risk strains not included in the vaccine -- 20.7% to 16.4% (HR 0.79, 95% CI 0.60-1.04)

The investigators found no significant differences between pre-vaccine and vaccine eras for age groups 20 to 24, 25 to 29, 30 to 39, 40 to 49, or 50 to 59.

Further analysis of the 14 to 19 age group showed that vaccinated participants had a higher number of lifetime sex partners (=3, 57.6% versus 37.9% of unvaccinated participants, P<0.05).

In a multivariate analysis, the association between vaccination history and HPV prevalence increased (adjusted prevalence rate 0.18, 95% CI 0.07-0.47). Estimated effectiveness of at least one vaccine dose was 82%.

"Our data suggest an early impact of HPV vaccination on vaccine type prevalence among females in the United States and a high vaccine effectiveness against vaccine type infection," Markowitz and colleagues concluded. "The decline in vaccine type prevalence is higher than expected and could be due to herd immunity from vaccination, vaccine effectiveness of a series involving less than three doses, and/or changes in sexual behavior that we did not measure."

A principal investigator in the HPV vaccine trials said the results are encouraging but suggested that the true effects remain to be determined with increased experience and longer follow-up.

"It's a substantial drop in vaccine-related HPV types, particularly in light of the low rate of vaccination in the U.S.," Warner Huh, MD, of the University of Alabama at Birmingham, told MedPage Today. "It really speaks to the potential benefits and effectiveness of the vaccine in the U.S. population -- and is consistent with what we are seeing in Australia, which has one of the highest vaccination rates in girls in the world.

"However, it's surprising how much [the infection rate] dropped and may be a reflection of herd immunity, but it's too early to make that final conclusion."

The study was supported by the CDC.

The authors reported no potential conflicts of interest.

Charles Bankhead

Staff Writer

Working from Houston, home to one of the world's largest medical complexes, Charles Bankhead has more than 20 years of experience as a medical writer and editor. His career began as a science and medical writer at an academic medical center. He later spent almost a decade as a writer and editor for Medical World News, one of the leading medical trade magazines of its era. His byline has appeared in medical publications that have included Cardio, Cosmetic Surgery Times, Dermatology Times, Diagnostic Imaging, Family Practice, Journal of the National Cancer Institute, Medscape, Oncology News International, Oncology Times, Ophthalmology Times, Patient Care, Renal and Urology News, The Medical Post, Urology Times, and the International Medical News Group newspapers. He has a BA in journalism and MA in mass communications, both from Texas Tech University.